| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00310-1349-30 | 00310-1349 | Osimertinib | Tagrisso | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 13, 2015 | In Use | |
| 65597-0402-28 | 65597-0402 | pexidartinib | Turalio | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R, KIT, FLT3 | Oral | Aug 2, 2019 | Jan 31, 2024 | No Longer Used |
| 60505-2900-08 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
| 72205-0118-28 | 72205-0118 | Sunitinib Malate | Sunitinib Malate | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Jun 1, 2025 | In Use | |
| 70771-1395-03 | 70771-1395 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 69097-0578-56 | 69097-0578 | nilotinib | NILCEYA | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2025 | In Use | |
| 59651-0542-15 | 59651-0542 | DASATINIB | DASATINIB | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 42388-0023-57 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 9, 2023 | In Use | |
| 00002-2980-26 | 00002-2980 | Selpercatinib | RETEVMO | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
| 00378-2246-93 | 00378-2246 | imatinib | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2017 | In Use | |
| 70709-0154-80 | 70709-0154 | Dasatinib | PHYRAGO | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 22, 2025 | In Use | |
| 00093-8231-28 | 00093-8231 | Sunitinib Malate | Sunitinib Malate | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec 22, 2021 | In Use | |
| 42291-0904-28 | 42291-0904 | Sunitinib Malate | Sunitinib Malate | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Oct 11, 2023 | In Use | |
| 67184-0533-01 | 67184-0533 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
| 00078-0698-51 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Apr 28, 2017 | In Use | |
| 72205-0239-63 | 72205-0239 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 20, 2025 | In Use | |
| 50242-0623-42 | 50242-0623 | ENTRECTINIB | Rozlytrek | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Oct 20, 2023 | In Use | |
| 59651-0467-29 | 59651-0467 | SUNITINIB MALATE | SUNITINIB MALATE | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Mar 14, 2024 | In Use | |
| 54868-5447-00 | 54868-5447 | Erlotinib Hydrochloride | Tarceva | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct 13, 2005 | In Use | |
| 69539-0091-30 | 69539-0091 | Erlotinib Hydrochloride | Erlotinib Hydrochloride | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 11, 2021 | In Use | |
| 57962-0070-28 | 57962-0070 | Ibrutinib | IMBRUVICA | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Dec 20, 2017 | In Use | |
| 72205-0119-28 | 72205-0119 | Sunitinib Malate | Sunitinib Malate | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Jun 1, 2025 | In Use | |
| 00003-0855-22 | 00003-0855 | Dasatinib | Sprycel | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 28, 2010 | In Use | |
| 69539-0090-30 | 69539-0090 | Erlotinib Hydrochloride | Erlotinib Hydrochloride | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 11, 2021 | In Use | |
| 72064-0120-30 | 72064-0120 | avapritinib | Ayvakit | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Oral | Jan 9, 2020 | In Use |
Found 12159 results — Export these results
Home